Inhibition of the Hg pathway (using Smo antagonists or by knocking out the Smo) can reduce the activation of quiescent HSCs, reduce the production of MYF HSCs, and reduce the degree of hepatic fibrosis (Table 1). This evidence concerns the gene SMO and Hepatic fibrosis.